Nagata, Y.; Minato, A.; Aono, H.; Kimuro, R.; Higashijima, K.; Tomisaki, I.; Harada, K.; Miyamoto, H.; Fujimoto, N.
Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma. Int. J. Mol. Sci. 2024, 25, 10348.
https://doi.org/10.3390/ijms251910348
AMA Style
Nagata Y, Minato A, Aono H, Kimuro R, Higashijima K, Tomisaki I, Harada K, Miyamoto H, Fujimoto N.
Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma. International Journal of Molecular Sciences. 2024; 25(19):10348.
https://doi.org/10.3390/ijms251910348
Chicago/Turabian Style
Nagata, Yujiro, Akinori Minato, Hisami Aono, Rieko Kimuro, Katsuyoshi Higashijima, Ikko Tomisaki, Kenichi Harada, Hiroshi Miyamoto, and Naohiro Fujimoto.
2024. "Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma" International Journal of Molecular Sciences 25, no. 19: 10348.
https://doi.org/10.3390/ijms251910348
APA Style
Nagata, Y., Minato, A., Aono, H., Kimuro, R., Higashijima, K., Tomisaki, I., Harada, K., Miyamoto, H., & Fujimoto, N.
(2024). Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma. International Journal of Molecular Sciences, 25(19), 10348.
https://doi.org/10.3390/ijms251910348
